How will your patients benefit

Short Treatment Time Comfortable Treatment Long lasting results

SLT for Glaucoma with Dr. Nate Lighthizer

In an interactive webinar, Dr. Nate Lighthizer discusses Lumenis SLT’s advantages for glaucoma patients and referral decisions for this trusted laser treatment.

OptiLIGHT Unlocks Possibilities for Dry Eye Patients and Practices

Dr. Carly Rose explains how adopting more advanced DED tools like OptiLIGHT in her practice helps her achieve more for her patients, even with less time.

Practice Benefits

Rapid return on investment Increase your patient satisfaction Grow your business Benefit from a short return on investment, expand your practice’s offering with laser hair removal technology and attract new customers seeking fast, comfortable & affordable laser hair removal treatments.

About

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).

A New Dawn for Dry Eye: Lumenis OptiLight™

Eyes on Eyecare gathers insights from patients and practitioners on the first and only FDA-approved IPL for dry eye management: OptiLight by Lumenis.

Yan et al. (2021): The Efficacy of Intense Pulsed Light Combined With Meibomian Gland Expression for the Treatment of Dry Eye Disease Due to Meibomian Gland Dysfunction: A Multicenter, Randomized Controlled Trial

In a prospective, multicenter, randomized control trial, Lumenis IPL with OPT™ combined with MGX significantly improved signs and symptoms of DED due to MGD.

Fishman et al (2020): Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light

An in-vitro study demonstrated that, with settings used for treatment of dry eye due to meibomian gland dysfunction (MGD), Lumenis IPL with OPTTM destroyed an isolated Demodex mite.

Choi et al (2019): Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines

In a prospective, single arm study, Lumenis IPL with OPT™ improved signs and symptoms of Dry Eye Disease due to MGD, and decreased tear levels of key inflammation markers. The decrease of two of these markers were correlated with improvement in meibum expressibility.

Arita et al. (2019): Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dsyfunction

The results of a prospective, random control trial show the combination of Lumenis IPL with OPT™ and Meibomian Gland Expression (MGX) improves tear film homeostasis and ameliorates ocular symptoms in patients with refractory Meibomian Gland Dysfunction (MGD).